PMID- 20090337
OWN - NLM
STAT- MEDLINE
DCOM- 20100713
LR  - 20131121
IS  - 1421-9867 (Electronic)
IS  - 0012-2823 (Linking)
VI  - 81
IP  - 4
DP  - 2010
TI  - Does pretreatment with lansoprazole influence Helicobacter pylori eradication 
      rate and quality of life?
PG  - 218-22
LID - 10.1159/000260416 [doi]
AB  - BACKGROUND/AIMS: It is controversial whether pretreatment with a proton pump 
      inhibitor (PPI) before Helicobacter pylori eradication treatment decreases the 
      eradication rate. To determine the effects of pretreatment with lansoprazole 
      alone, followed by an H. pylori eradication regimen (lansoprazole 30 mg, 
      amoxicillin 750 mg and clarithromycin 200 mg twice daily for 1 week), on the 
      eradication rate and quality of life (QoL) of the patient. METHODS: Patients with 
      H. pylori-positive peptic ulcer were randomly assigned to two groups. The 
      patients received either lansoprazole (30 mg) once daily for 6-8 weeks before H. 
      pylori eradication (group A), or eradication treatment and then lansoprazole (30 
      mg) for 6-8 weeks (group B). To assess the QoL of the patients, the 
      Gastrointestinal Symptom Rating Scale (GSRS) questionnaire was evaluated. 
      RESULTS: A total of 116 patients were enrolled. The cure rates were 78.9% in 
      group A and 78.0% in group B. In both groups, GSRS analysis showed a significant 
      improvement of the overall GSRS score at the assessment of eradication efficacy, 
      compared to baseline; there was no difference between the groups. CONCLUSION: 
      With this H. pylori eradication regimen, there was no difference in the cure 
      rates and QoL associated with PPI pretreatment.
FAU - Inoue, Masafumi
AU  - Inoue M
AD  - Department of Gastroenterology and Hepatology, Okayama University Graduate School 
      of Medicine, Dentistry, and Pharmaceutical Science, Okayama, Japan.
FAU - Okada, Hiroyuki
AU  - Okada H
FAU - Hori, Shinichiro
AU  - Hori S
FAU - Kawahara, Yoshiro
AU  - Kawahara Y
FAU - Kawano, Seiji
AU  - Kawano S
FAU - Takenaka, Ryuta
AU  - Takenaka R
FAU - Toyokawa, Tatsuya
AU  - Toyokawa T
FAU - Onishi, Yasuhiro
AU  - Onishi Y
FAU - Shiratori, Yasushi
AU  - Shiratori Y
FAU - Yamamoto, Kazuhide
AU  - Yamamoto K
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20100120
PL  - Switzerland
TA  - Digestion
JT  - Digestion
JID - 0150472
RN  - 0 (2-Pyridinylmethylsulfinylbenzimidazoles)
RN  - 0 (Proton Pump Inhibitors)
RN  - 0K5C5T2QPG (Lansoprazole)
RN  - 804826J2HU (Amoxicillin)
RN  - H1250JIK0A (Clarithromycin)
SB  - IM
MH  - 2-Pyridinylmethylsulfinylbenzimidazoles/*administration & dosage
MH  - Administration, Oral
MH  - Adult
MH  - Amoxicillin/*administration & dosage
MH  - Clarithromycin/*administration & dosage
MH  - Dose-Response Relationship, Drug
MH  - Drug Administration Schedule
MH  - Drug Therapy, Combination
MH  - Duodenal Ulcer/drug therapy/microbiology/pathology
MH  - Female
MH  - Follow-Up Studies
MH  - Helicobacter Infections/diagnosis/*drug therapy
MH  - Helicobacter pylori/*drug effects/isolation & purification
MH  - Humans
MH  - Lansoprazole
MH  - Logistic Models
MH  - Male
MH  - Middle Aged
MH  - Proton Pump Inhibitors/administration & dosage
MH  - *Quality of Life
MH  - Risk Assessment
MH  - Severity of Illness Index
MH  - Statistics, Nonparametric
MH  - Stomach Ulcer/drug therapy/microbiology/pathology
MH  - Treatment Outcome
EDAT- 2010/01/22 06:00
MHDA- 2010/07/14 06:00
CRDT- 2010/01/22 06:00
PHST- 2009/08/20 00:00 [received]
PHST- 2009/11/16 00:00 [accepted]
PHST- 2010/01/22 06:00 [entrez]
PHST- 2010/01/22 06:00 [pubmed]
PHST- 2010/07/14 06:00 [medline]
AID - 000260416 [pii]
AID - 10.1159/000260416 [doi]
PST - ppublish
SO  - Digestion. 2010;81(4):218-22. doi: 10.1159/000260416. Epub 2010 Jan 20.